EGFR — Drug Target

All drugs that target EGFR — marketed and clinical-stage. Includes 10 drug classes acting on this target.

Drug classes

EGFR tyrosine kinase inhibitor · Chemotherapy regimen · Tyrosine kinase inhibitor · Monoclonal antibody and taxane · Platinum-based chemotherapy, EGFR inhibitor · Antineoplastic agents · EGFR inhibitor · Monoclonal antibody-drug conjugate · Monoclonal antibody · tyrosine kinase inhibitor

Marketed (1)

• Sequential and maintenance icotinib · Betta Pharmaceuticals Co., Ltd. · EGFR tyrosine kinase inhibitor · Oncology
  Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.

Phase 3 pipeline (9)

• mFOLFOX6 plus cetuximab · West China Hospital · Chemotherapy regimen · Oncology
  mFOLFOX6 plus cetuximab is a chemotherapy regimen that targets cancer cells by inhibiting DNA synthesis and inducing apoptosis.
• targeted drug · Nanfang Hospital, Southern Medical University · Tyrosine kinase inhibitor · Oncology
  This targeted drug works by binding to a specific protein on cancer cells, preventing them from growing and dividing.
• nimotuzumab plus paclitaxel · Biotech Pharmaceutical Co., Ltd. · Monoclonal antibody and taxane · Oncology
  Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while paclitaxel is a taxane that inhibits cell division.
• mCapOX plus cetuximab · West China Hospital · Platinum-based chemotherapy, EGFR inhibitor · Oncology
  mCapOX is a chemotherapy drug that works by inhibiting DNA replication, while cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR).
• Placebo Gefitinib Tablets · Hangzhou ACEA Pharmaceutical Research Co., Ltd. · EGFR tyrosine kinase inhibitor · Oncology
  Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
• EGFR-TK Inhibitor · Xinqiao Hospital of Chongqing · EGFR tyrosine kinase inhibitor · Oncology
  This drug inhibits tyrosine kinase activity of the epidermal growth factor receptor (EGFR), blocking downstream signaling that drives cancer cell proliferation.
• ZD1839 (Gefitinib) · AstraZeneca · EGFR tyrosine kinase inhibitor · Oncology
  ZD1839 (Gefitinib) is a small molecule that inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase.
• Tarceva (erlotinib HCl) · Genentech, Inc. · EGFR tyrosine kinase inhibitor · Oncology
  Tarceva (erlotinib HCl) works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase.
• cetuximab + cisplatin + vinorelbine · Merck KGaA, Darmstadt, Germany · Antineoplastic agents · Oncology
  Cetuximab targets the epidermal growth factor receptor (EGFR), while cisplatin and vinorelbine work by interfering with DNA replication and cell division.

Phase 2 pipeline (16)

• Amivantamab IV · Janssen Research & Development, LLC · EGFR inhibitor · Oncology
  Targeting EGFR
• Disitamab Vedotin for injection · RemeGen Co., Ltd. · Monoclonal antibody-drug conjugate · Oncology
  Disitamab vedotin is a monoclonal antibody-drug conjugate that targets the epidermal growth factor receptor (EGFR) and delivers a microtubule inhibitor to cancer cells.
• Icotinib Hydrochloride Tablets · Betta Pharmaceuticals Co., Ltd. · Tyrosine kinase inhibitor · Oncology
  Tyrosine kinase inhibitor
• Gefitinib, Cisplatin and Radiotherapy · AstraZeneca · EGFR tyrosine kinase inhibitor · Oncology
  Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
• Cetuximab Radioimmunotherapy · Arbeitsgemeinschaft medikamentoese Tumortherapie · Monoclonal antibody · Oncology
  Cetuximab Radioimmunotherapy targets and destroys cancer cells by binding to the epidermal growth factor receptor (EGFR) and delivering a radioactive payload.
• Afatinib treatment · Sheba Medical Center · EGFR inhibitor · Oncology
  Epidermal growth factor receptor (EGFR) inhibitor
• Gefitinib, raltitrexed · AstraZeneca · Tyrosine kinase inhibitor · Oncology
  Tyrosine kinase inhibitor
• Anti-EGFR-Containing Regimen · Hoffmann-La Roche · EGFR inhibitor · Oncology
  Inhibits the epidermal growth factor receptor (EGFR)
• Icotinib with concurrent radiotherapy · Betta Pharmaceuticals Co., Ltd. · EGFR tyrosine kinase inhibitor · Oncology
  Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
• Cetuximab Injection [Erbitux] · Shanghai Henlius Biotech · EGFR inhibitor · Oncology
  Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), preventing cancer cell growth and proliferation.
• EKB-569 · Wyeth is now a wholly owned subsidiary of Pfizer · tyrosine kinase inhibitor · Oncology
  EKB-569 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
• Erlotinib, standard dose · Hoffmann-La Roche · EGFR tyrosine kinase inhibitor · Oncology
  Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase.
• Cetuximab Induction · Arbeitsgemeinschaft medikamentoese Tumortherapie · EGFR inhibitor · Oncology
  Cetuximab is a monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling.
• Carbo, 5FU, Cetuximab · Groupe Oncologie Radiotherapie Tete et Cou · Antineoplastic agents · Oncology
  Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells.
• IV cetuximab · Association pour la Recherche sur le Temps Biologique et la Chronothérapie · EGFR inhibitor · Oncology
  Inhibits epidermal growth factor receptor (EGFR)
• AZD3759 · Guangdong Association of Clinical Trials · EGFR inhibitor · Oncology
  AZD3759 is a small molecule inhibitor of the EGFR pathway.